|AIRvance™ Bone Screw System Gains Additional FDA Clearance|
The AIRvance™ Bone Screw System Is Now Suitable for the Performance of a Hyoid Suspension Procedure, Which Can Be Used in Combination with Other Procedures for the Treatment of Obstructive Sleep Apnea
MINNEAPOLIS – Feb. 13, 2013 – Medtronic announced today that it has received Food and Drug Administration (FDA) clearance for its AIRvance™ Bone Screw System that allows surgeons to perform a hyoid suspension procedure independently or in combination with other procedures for the treatment of obstructive sleep apnea (OSA).
“This is good news for ENT surgeons and their patients with OSA,” says M. Boyd Gillespie, M.D., Professor of Otolaryngology-Head and Neck Surgery at the Medical University of South Carolina, “We now have the option of treating patients with either or both procedures based on what’s best for the patient.” Gillespie adds, “There are many places in the airway that can be obstructed and contribute to OSA. Surgeons can now perform the hyoid suspension procedure as a stand-alone procedure to treat hypopharyngeal-based obstructions or in conjunction with other targeted procedures as a comprehensive surgical approach to treating OSA.”
In addition, the American Academy of Otolaryngology – Head and Neck Surgery recently endorsed tongue suspension as an effective treatment for managing patients with OSA.
About The Medtronic AIRvance™ Bone Screw System
Since the AIRvance™ Bone Screw System was introduced in 1999 it has been used to treat more than 15,000 people worldwide with sleep disordered breathing problems including snoring and OSA. For more information, visit:
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
– end –
Medtronic Media Contacts:
Natalie St. Denis, Public Relations, +1-720-890-3314
Jeff Warren, Investor Relations, 763-505-2696